External broker reports(aggregated public sources), ICICI Securities Ltd

ICICI Securities Limited

External broker reports(aggregated public sources)

ICICI Securities Ltd

ICICI Securities Limited provides investment services. The Company provides corporate and investment banking, securities, wealth management, retail brokerage, initial public offerings, and advisory services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).</li><li>Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.34 billion.</li><li>Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.34 billion.Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon - Steady Performance; Focus on Viatris Integration...

Biocon - Steady Performance; Focus on Viatris Integration

Biocon Ltd (BIOCON) - Steady Performance; Focus on Viatris Integration...

External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Biocon reported a Consolidated EBITDA of Rs 471 Cr (EBITDA margins: 20.3%), which stood below our expectations.</li><li>The numbers got majorly impacted due to an increase in the R&amp;D Cost by 59% during the quarter.</li><li>The overall R&amp;D Costs have increased to Rs 242 Cr from Rs 146 Cr on a YoY basis, impacting the EBITDA margins which declined to 20.3% from expectations of 24.2%.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Biocon reported a Consolidated EBITDA of Rs 471 Cr (EBITDA margins: 20.3%), which stood below our expectations.The numbers got majorly impacted due to an increase in the R&amp;D Cost by 59% during the quarter.The overall R&amp;D Costs have increased to Rs 242 Cr from Rs 146 Cr on a YoY basis, impacting the EBITDA margins which declined to 20.3% from expectations of 24.2%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Thematic (Sector/Industry)

<ul><li>In Q2FY23, Pharma sector expected to be benefitted by factors like Currency depreciation, fall in raw material prices, low crude prices and correction in shipping prices could add to revenue growth and improvement in gross margins.</li><li>The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY.</li><li>Currency (Rs) has depreciated by 5.0% that could add major contribution to overall growth of 6.2% for last quarter.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

In Q2FY23, Pharma sector expected to be benefitted by factors like Currency depreciation, fall in raw material prices, low crude prices and correction in shipping prices could add to revenue growth and improvement in gross margins.The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY.Currency (Rs) has depreciated by 5.0% that could add major contribution to overall growth of 6.2% for last quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

India

Biocon Ltd., is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immunosuppressants and anti-diabetic drugs. Biocon also manufactures specialty enzymes and new enzyme applications besides providing clinical and custom research services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biocon Ltd (BIOS IN)

Biocon - Steady Performance; Focus on Viatris Integration...

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).

ICICI Securities Limited

Biocon - Steady Performance; Focus on Viatris Integration

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).

ICICI Securities Limited

Biocon Ltd (BIOCON) - Steady Performance; Focus on Viatris Integration...

Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene).

ICICI Securities Limited

Biocon - Margins Outlook on Lower Side

The overall R&D Costs have increased to Rs 242 Cr from Rs 146 Cr on a YoY basis, impacting the EBITDA margins which declined to 20.3% from...

Axis Direct

Pharma Q2fy23 Preview

The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)